NASDAQ:AKRXAkorn Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akorn.

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings data on Monday, May, 11th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.45. The business earned $204.69 million during the quarter, compared to the consensus estimate of $168.90 million. Akorn had a negative net margin of 55.64% and a positive return on equity of 8.53%. View Akorn's earnings history.

2 equities research analysts have issued 1 year target prices for Akorn's shares. Their forecasts range from $2.00 to $4.00. On average, they expect Akorn's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 873.1% from the stock's current price. View analysts' price targets for Akorn.

News articles about AKRX stock have trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Akorn.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn's stock is owned by a variety of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.38%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View institutional ownership trends for Akorn.

AKRX stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn. View insider buying and selling activity for Akorn.

One share of AKRX stock can currently be purchased for approximately $0.31.

Akorn has a market capitalization of $41.05 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

The official website for Akorn is www.akorn.com.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]